These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
200 related items for PubMed ID: 20139503
1. Characterization of morphologically benign biologically aggressive meningiomas. Rao S, Sadiya N, Doraiswami S, Prathiba D. Neurol India; 2009; 57(6):744-8. PubMed ID: 20139503 [Abstract] [Full Text] [Related]
2. Correlation between histological grade and MIB-1 and p53 immunoreactivity in meningiomas. Ozen O, Demirhan B, Altinörs N. Clin Neuropathol; 2005; 24(5):219-24. PubMed ID: 16167545 [Abstract] [Full Text] [Related]
3. Correlation between histological grade, MIB-1, p53, and recurrence in 69 completely resected primary intracranial meningiomas with a 6 year mean follow-up. Lanzafame S, Torrisi A, Barbagallo G, Emmanuele C, Alberio N, Albanese V. Pathol Res Pract; 2000; 196(7):483-8. PubMed ID: 10926326 [Abstract] [Full Text] [Related]
4. Immunohistochemical study of Ki-67 (MIB-1), p53 protein, p21WAF1, and p27KIP1 expression in benign, atypical, and anaplastic meningiomas. Amatya VJ, Takeshima Y, Sugiyama K, Kurisu K, Nishisaka T, Fukuhara T, Inai K. Hum Pathol; 2001 Sep; 32(9):970-5. PubMed ID: 11567227 [Abstract] [Full Text] [Related]
5. Detection of progesterone receptor and the correlation with Ki-67 labeling index in meningiomas. Mukherjee S, Ghosh SN, Chatterjee U, Chatterjee S. Neurol India; 2011 Sep; 59(6):817-22. PubMed ID: 22234191 [Abstract] [Full Text] [Related]
6. [Expression of HER2/neu in meningiomas: an immunohistochemistry and fluorescence in situ hybridization study]. Wang CL, Mei JH, Wang SS, Xu S, Xu LL, Xiong YF. Zhonghua Bing Li Xue Za Zhi; 2010 Mar; 39(3):156-60. PubMed ID: 20450760 [Abstract] [Full Text] [Related]
7. Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas. Bozkurt SU, Ayan E, Bolukbasi F, Elmaci I, Pamir N, Sav A. APMIS; 2009 Sep; 117(9):651-9. PubMed ID: 19703125 [Abstract] [Full Text] [Related]
8. Expression of Ki-67 and p53 in meningiomas. Pavelin S, Becic K, Forempoher G, Mrklic I, Pogorelic Z, Titlic M, Andelinovic S. Neoplasma; 2013 Sep; 60(5):480-5. PubMed ID: 23790165 [Abstract] [Full Text] [Related]
9. Recurrence of benign meningiomas: predictive value of proliferative index, BCL2, p53, hormonal receptors and HER2 expression. Abdelzaher E, El-Gendi SM, Yehya A, Gowil AG. Br J Neurosurg; 2011 Dec; 25(6):707-13. PubMed ID: 20979437 [Abstract] [Full Text] [Related]
10. Expression of progestrone receptor and proliferative marker ki 67 in various grades of meningioma. Shayanfar N, Mashayekh M, Mohammadpour M. Acta Med Iran; 2010 Dec; 48(3):142-7. PubMed ID: 21137648 [Abstract] [Full Text] [Related]
18. The significance of immunohistochemical expression of Ki-67, p53, p21, and p16 in meningiomas tissue arrays. Terzi A, Saglam EA, Barak A, Soylemezoglu F. Pathol Res Pract; 2008 Jan; 204(5):305-14. PubMed ID: 18374497 [Abstract] [Full Text] [Related]
19. Correlation of p63 protein expression with histological grade of meningiomas: an immunohistochemical study. Mittal S, Jain D, Roy S, Mehta VS. Int J Surg Pathol; 2012 Aug; 20(4):349-54. PubMed ID: 22287651 [Abstract] [Full Text] [Related]
20. Proliferation and progesterone receptor status in benign meningiomas are not age dependent. Roser F, Nakamura M, Ritz R, Bellinzona M, Dietz K, Samii M, Tatagiba MS. Cancer; 2005 Aug 01; 104(3):598-601. PubMed ID: 15952201 [Abstract] [Full Text] [Related] Page: [Next] [New Search]